Effect of the Rs1051730–Rs16969968 Variant and Smoking Cessation Treatment: A Meta-Analysis

Tiffany Leung; Andrew Bergen; Marcus Robert Munafò; Kim De Ruyck; Peter Selby; Vincenzo De Luca

doi:10.2217/pgs.15.34

Effect of the Rs1051730–Rs16969968 Variant and Smoking Cessation Treatment: A Meta-Analysis

Tiffany Leung, Andrew Bergen, Marcus Robert Munafò, Kim De Ruyck, Peter Selby, Vincenzo De Luca

Vice Chancellor's Office

Research output: Contribution to journal › Article › peer-review

20 Citations (SciVal)

Abstract

Objective: To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT).

Methods: We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants.

Results: There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95% CI: 0.77 to 1.23, z = 0.27, p = 0.791).

Conclusion: There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT.

Original language	English
Pages (from-to)	713-720
Number of pages	8
Journal	Pharmacogenomics
Volume	16
Issue number	7
Early online date	7 May 2015
DOIs	https://doi.org/10.2217/pgs.15.34
Publication status	Published - 31 May 2015

Keywords

CHRNA3
CHRNA5
genetics
NRT
smoking

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs.15.34

Cite this

@article{3a2b55a465e7480fafe1bebc5b7e291a,

title = "Effect of the Rs1051730–Rs16969968 Variant and Smoking Cessation Treatment: A Meta-Analysis",

abstract = "Objective: To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT). Methods: We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants. Results: There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95\% CI: 0.77 to 1.23, z = 0.27, p = 0.791). Conclusion: There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT.",

keywords = "CHRNA3, CHRNA5, genetics, NRT, smoking",

author = "Tiffany Leung and Andrew Bergen and Munaf{\`o}, \{Marcus Robert\} and \{De Ruyck\}, Kim and Peter Selby and \{De Luca\}, Vincenzo",

year = "2015",

month = may,

day = "31",

doi = "10.2217/pgs.15.34",

language = "English",

volume = "16",

pages = "713--720",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Taylor and Francis",

number = "7",

}

TY - JOUR

T1 - Effect of the Rs1051730–Rs16969968 Variant and Smoking Cessation Treatment

T2 - A Meta-Analysis

AU - Leung, Tiffany

AU - Bergen, Andrew

AU - Munafò, Marcus Robert

AU - De Ruyck, Kim

AU - Selby, Peter

AU - De Luca, Vincenzo

PY - 2015/5/31

Y1 - 2015/5/31

N2 - Objective: To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT). Methods: We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants. Results: There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95% CI: 0.77 to 1.23, z = 0.27, p = 0.791). Conclusion: There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT.

AB - Objective: To assess if the allelic variations of rs16969968/rs1051730 in the CHRNA5-CHRNA3-CHRNB4 gene cluster are associated with smoking cessation after nicotine replacement therapy (NRT). Methods: We searched for NRT studies published from 2000-2013 that reported counts for allelic variation of rs16969968/rs1051730 and measured abstinence rates at the end of NRT treatment. We identified four studies which met the criteria, giving us a test sample of 2036 participants. Results: There was no effect of rs16969968/rs1051730 in influencing the success rate at the end of NRT (n = 6, effect size [ES]: 0.969, 95% CI: 0.77 to 1.23, z = 0.27, p = 0.791). Conclusion: There is no robust evidence that allelic variations of rs16969968 or rs1051730 are associated with smoking cessation after NRT.

KW - CHRNA3

KW - CHRNA5

KW - genetics

KW - NRT

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=84930737839&partnerID=8YFLogxK

U2 - 10.2217/pgs.15.34

DO - 10.2217/pgs.15.34

M3 - Article

C2 - 25950378

AN - SCOPUS:84930737839

SN - 1462-2416

VL - 16

SP - 713

EP - 720

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 7

ER -

Effect of the Rs1051730–Rs16969968 Variant and Smoking Cessation Treatment: A Meta-Analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this